Connor, Clark & Lunn Investment Management Ltd. Karyopharm Therapeutics Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	BUY	$0.72 - $1.66 $3,666 - $8,454	5,093 Added 7.15%	76,317 $115,000
Q4 2023 Feb 09, 2024	BUY	$0.68 - $1.31 $24,442 - $47,087	35,945 Added 101.89%	71,224 $61,000
Q3 2023 Nov 13, 2023	SELL	$1.14 - $1.81 $2,520 - $4,001	-2,211 Reduced 5.9%	35,279 $47,000
Q2 2023 Aug 10, 2023	SELL	$1.79 - $4.59 $268,428 - $688,316	-149,960 Reduced 80.0%	37,490 $67,000
Q1 2023 May 09, 2023	SELL	$2.84 - $3.92 $695,311 - $959,725	-244,828 Reduced 56.64%	187,450 $729,000
Q4 2022 Feb 10, 2023	BUY	$2.48 - $5.93 $686,575 - $1.64 Million	276,845 Added 178.11%	432,278 $1.47 Million
Q3 2022 Nov 10, 2022	BUY	$4.08 - $5.82 $446,576 - $637,028	109,455 Added 238.06%	155,433 $849,000
Q2 2022 Aug 05, 2022	BUY	$4.15 - $8.37 $190,808 - $384,835	45,978 New	45,978 $207,000
Q3 2019 Nov 13, 2019	SELL	$5.66 - $11.85 $326,474 - $683,519	-57,681 Closed	0 $0
Q2 2019 Aug 07, 2019	SELL	$4.32 - $6.43 $316,548 - $471,158	-73,275 Reduced 55.95%	57,681 $346,000
Q1 2019 May 08, 2019	BUY	$4.12 - $10.25 $539,538 - $1.34 Million	130,956 New	130,956 $765,000

Others Institutions Holding KPTI

# of Institutions

Shares Held

56.5M

Call Options Held

258K

Put Options Held

81.2K

Vanguard Group Inc Valley Forge, PA

7.65M
Shares

$5.05 Million
0.0% of portfolio
Eversept Partners, LP New York, NY

5.55M
Shares

$3.66 Million
0.36% of portfolio
Palo Alto Investors LP Palo Alto, CA

5.1M
Shares

$3.37 Million
0.58% of portfolio
Adage Capital Partners Gp, L.L.C. Boston, MA

4.32M
Shares

$2.85 Million
0.01% of portfolio
Black Rock Inc. New York, NY

4.17M
Shares

$2.75 Million
0.0% of portfolio

View Full List

About Karyopharm Therapeutics Inc.

Ticker KPTI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 79,806,600
Market Cap $52.7M
Description
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...

More about KPTI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account